Creating a vaccine for respiratory syncytial virus in older adults
Development of an RSV vaccine for the elderly
This study is working on a new vaccine for respiratory syncytial virus (RSV) to help protect older adults, who are often hit hard by this virus, by using special particles that look like the virus to boost their immune system.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Univ of Massachusetts Med Sch Worcester NIH-funded |
| Lab location | 1 site (Worcester, United States) |
| Project ID | NIH-10795110 on NIH RePORTER |
What this research studies
This research aims to develop a vaccine specifically for respiratory syncytial virus (RSV) targeting elderly populations, who are significantly affected by this virus. The project utilizes novel virus-like particles that mimic the virus to stimulate a strong immune response. By testing these vaccine candidates in animal models, the researchers hope to identify an effective formulation that can be translated into human clinical trials. The ultimate goal is to reduce the high rates of RSV-related hospitalizations and deaths among older adults.
Who could benefit from this research
Good fit: Ideal candidates for this research are older adults, particularly those over the age of 60, who are at higher risk for severe RSV infections.
Not a fit: Patients who are younger than 60 or those who have already been vaccinated against RSV may not receive direct benefits from this research.
Why it matters
Potential benefit: If successful, this research could lead to a vaccine that significantly lowers the incidence of RSV infections and related complications in elderly patients.
How similar studies have performed: Previous research has shown promise in developing vaccines using similar virus-like particle technology, indicating a potential for success in this approach.
Where this research is happening
Worcester, United States
- Univ of Massachusetts Med Sch Worcester — Worcester, United States (Active)
Researchers
- Principal investigator: Morrison, Trudy G. — Univ of Massachusetts Med Sch Worcester
- Study coordinator: Morrison, Trudy G.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.